Junichi Soh

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

ASO Visual Abstract: Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.

ASO Visual Abstract: Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.

Journal: Annals of surgical oncology

Published: June 20, 2026

Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.

Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.

Journal: General thoracic and cardiovascular surgery

Published: April 17, 2026

Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study).

Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study).

Journal: Annals of surgical oncology

Published: March 25, 2026

Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.

Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 18, 2025

Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer.

Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer.

Journal: Annals of surgical oncology

Published: December 03, 2025

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study).

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 14, 2025

Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis.

Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis.

Journal: JTO clinical and research reports

Published: August 21, 2025

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

Journal: Cells

Published: July 30, 2025

Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).

Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 30, 2025

Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status.

Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Published: April 29, 2025

Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).

Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).

Journal: The Annals of thoracic surgery

Published: April 18, 2025

Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR Study.

Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR Study.

Journal: Pathology international

Published: April 17, 2025

Showing 1-12 of 184

Last Updated: 09/26/2026